Ng P C, Fok T F, Lee C H, Wong W, Cheung K L
Department of Paediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong.
J Paediatr Child Health. 1997 Apr;33(2):148-50. doi: 10.1111/j.1440-1754.1997.tb01018.x.
To report our clinical experience on the use of oral erythromycin for the treatment of severe gastrointestinal dysmotility in preterm infants.
A case series study of seven preterm infants (six were very low birthweight) with severe intestinal dysmotility in a tertiary neonatal centre.
All responded favourably without adverse effects and tolerated full enteral feeding within 1-2 weeks of the commencement of the drug.
As prolonged total parenteral nutrition carries significant risk of complications, this therapy could be considered in selected preterm infants who fail to establish enteral feeding after an extended period, and in whom an anatomically obstructive lesion of the gastrointestinal tract has been excluded. Meanwhile, we would caution against the widespread implementation of this therapeutic approach until formal evaluation by randomized controlled trials have established the exact role of erythromycin, or its analogues, in the treatment of intestinal dysmotility in preterm infants.
报告我们使用口服红霉素治疗早产儿严重胃肠动力障碍的临床经验。
在一家三级新生儿中心对7例患有严重肠道动力障碍的早产儿（6例为极低出生体重儿）进行病例系列研究。
所有患儿反应良好，无不良反应，且在开始用药后1 - 2周内耐受全肠内喂养。
由于长期全胃肠外营养有显著的并发症风险，对于经过较长时间仍未能建立肠内喂养且已排除胃肠道解剖性梗阻病变的特定早产儿，可考虑采用这种治疗方法。同时，在随机对照试验进行正式评估确定红霉素或其类似物在治疗早产儿肠道动力障碍的确切作用之前，我们谨慎反对广泛实施这种治疗方法。
